Skip to content

A open multi-center clinical study on cefotaxime sodium and sulbactam sodium for injection (2:1) for treatment of respiratory and urinary tract infection

A open multi-center clinical study on Cefotaxime sodium and sulbactam sodium for injection(2:1) for treatment of respiratory and urinary tract acute bacterial infection

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-11001590
Enrollment
Unknown
Registered
2011-08-17
Start date
2011-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory and urlnary tract acute bacterial infection

Interventions

Test group:1.5-3.0g, iv, bid or tid for 5-12 days Serious infections1.0-1.5g, iv, tid or qid for 5-12 days

Sponsors

The 1st Affiliated Hospital of Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. patients who qualify for moderate and severe acute respiratory or urinary tract bacterial infection of acute bacterial infections need for systemic antibiotic therapy; 2. Age>18 years old, both gender; 3. Women of childbearing age were to be negative pregnancy test and agree to take contraceptive measures during the trial; 4. patients were volunteers and signed informed consent form; 5. patients did not participate in other clinical trials.

Exclusion criteria

Exclusion criteria: 1. Patients were hypersusceptibility to the test drug or other penicillins, beta-lactamase inhibitor; 2. Pregnant and Lactating women; 3. Patients have severe liver, kidney,cardiovascular,cerebrovascular,endocrine and hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer or mental illness; 4. Patients who were complicated by other diseases and thougt to affect efficacy evaluations or poor compliance.

Design outcomes

Primary

MeasureTime frame
incidence;

Secondary

MeasureTime frame
overall effect;

Contacts

Public Contacttingwang
wmrd@welman.com.cn+86 20 38868707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026